Combination therapy with adagrasib and pembrolizumab has demonstrated increased CD8 infiltration and anti-tumor response by downregulating CXCL1, CXCL8, VEGF, and CD73, reshaping the TME and facilitating TIL infiltration, [439]. Here, CXCL8 is linked to neoplasm.